Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Press Room Contact Us Sitemap Sign In Register
Link to Homepage About BrightFocus
BrightFocus
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Sign up for Email Notifications
If you would like to be notified when funding or meeting opportunities are announced please click on the link below.

Sign up for new announcements.

Please add ResearchGrants@BrightFocus.org to your institution’s white list to insure that the notification is not blocked by your organization’s SPAM filters.

This email list is not sold or distributed, and serves only as an annual reminder of the availability of research support through the BrightFocus Foundation (www.brightfocus.org). Please follow instructions on the notification emails for removal requests.

 
 
BrightFocus Research Grants Funding
Grant Funding for Alzheimer's Research
Grant Funding for Macular Degeneration Research
Grant Funding for Glaucoma Research
 

 

Macular Degeneration Research
Completed Award

Dr. Vinit Mahajan

Vinit B. Mahajan, M.D., Ph.D.

University of Iowa
Iowa City, IA, United States

Title: Cytokine Signaling in the Foveal Choroid in AMD
Non-Technical Title: Cytokine Expression in Age-related Macular Degeneration

Co-PI(s):
Jessica Skeie, Ph.D.
University of Iowa

Duration: July 1, 2011 - June 30, 2014
Award Type: Standard
Award Amount: $100,000

Summary:

Cytokines are important proteins that cause inflammation and bleeding in age-related macular degeneration. We will use protein analysis methods to identify cytokines and their downstream signals that are highly expressed in the retina that is most susceptible to macular degeneration.

Details:

In neovascular stages of age‐related macular degeneration (wet AMD), leaky blood vessels grow into the retina and damage vision. These blood vessels are coaxed into the retina by a communication “cross‐talk” that may exist between hundreds of proteins and chemicals. Drs. Vinit Mahajan, Jessica Skeie and collaborators will use special methods to identify these proteins and chemicals from retina blood vessels that were surgically removed from the eyes of human donors who were either healthy or who had been diagnosed with AMD. Comparison of the profile between healthy and diseased eyes should present a number of cross‐talk candidates. The identities of these candidates may then inspire the design of combination drugs to treat AMD before the invasion of leaky blood vessels promotes rapid loss of vision.

Progress Updates:

Currently, inhibition of the VEGF “cytokine” signaling pathway is used to treat neovascular (wet) AMD and block the choroidal vessels that suddenly hemorrhage beneath the retina. The damage from the fluid that leaks from these vessels typically occurs at the center of the macula, called the fovea—the critical area for high resolution and high function vision. No particular anatomy of the choroid has explained the unique susceptibility of the subfoveal choroid in AMD. Drs. Vinit Mahajan’s and Jessica Skeie’s team are working to identify cytokine signaling pathways unique to the choroid surrounding the fovea. Using a method called proteomics to study several hundred proteins simultaneously, the team has identified unique sets of signaling proteins. These new proteins may be additional therapeutic targets for potential prevention of the choroidal vessel leakage and damage in wet AMD.

Investigator Biography:

Dr. Vinit Mahajan is an Assistant Professor of Ophthalmology and Visual Sciences at the University of Iowa and director of the Omics laboratory. He specializes in the surgical and medical care of vitreoretinal diseases such as macular degeneration, diabetic retinopathy, retinal detachment, uveitis, and inherited retinal dystrophies. Mahajan collaborates with leading scientists and physicians in the areas of proteomics and genomics. He believes translating the advances in molecular biology is the key to curing many forms of blindness. He contends that doctors who are as comfortable in the laboratory as they are in the operating room and clinic can accelerate the discovery process. Mahajan has published peer-reviewed papers in prestigious scientific journals, made presentations at national meetings, won research awards, and earned a U.S. patent. Mahajan has also been recognized by his peers since 2009 for inclusion in the Best Doctors in America.